Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter Phase 2 study of oral AT2220 in adults with Pompe disease
2008-002302-18Phase 2Completed
- Sponsor
- Amicus Therapeutics
- Start
- Sep 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of duvoglustat in Pompe disease (3 arms), sponsored by Amicus Therapeutics. Primary endpoints: Treatment-emergent physical exam changes and Safety and tolerability of AT2220. Started Sep 2008; status: completed.
02
Drugs
duvoglustat
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2008-002302-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002302-18.